Armata Pharmaceuticals Inc (ARMP)
2.36
+0.07
(+3.06%)
USD |
NYAM |
Sep 27, 16:00
Armata Pharmaceuticals Research and Development Expense (TTM): 32.40M for June 30, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2024 | 32.40M |
| March 31, 2024 | 32.18M |
| December 31, 2023 | 33.77M |
| September 30, 2023 | 35.41M |
| June 30, 2023 | 35.83M |
| March 31, 2023 | 36.59M |
| December 31, 2022 | 35.02M |
| September 30, 2022 | 30.26M |
| June 30, 2022 | 27.49M |
| March 31, 2022 | 23.69M |
| December 31, 2021 | 20.02M |
| September 30, 2021 | 20.18M |
| June 30, 2021 | 18.62M |
| March 31, 2021 | 16.04M |
| December 31, 2020 | 14.44M |
| September 30, 2020 | 11.13M |
| June 30, 2020 | 10.08M |
| March 31, 2020 | 10.51M |
| December 31, 2019 | 9.824M |
| September 30, 2019 | -0.107M |
| June 30, 2019 | -1.211M |
| March 31, 2019 | -2.595M |
| December 31, 2018 | -3.192M |
| September 30, 2018 | 6.161M |
| June 30, 2018 | 3.417M |
| Date | Value |
|---|---|
| March 31, 2018 | 2.855M |
| December 31, 2017 | 2.881M |
| September 30, 2017 | 2.593M |
| June 30, 2017 | 5.077M |
| March 31, 2017 | 5.188M |
| December 31, 2016 | 5.678M |
| September 30, 2016 | 6.091M |
| June 30, 2016 | 5.164M |
| March 31, 2016 | 5.00M |
| December 31, 2015 | 3.992M |
| September 30, 2015 | 3.89M |
| June 30, 2015 | 4.955M |
| March 31, 2015 | 5.766M |
| December 31, 2014 | 5.805M |
| September 30, 2014 | 5.802M |
| June 30, 2014 | 5.132M |
| March 31, 2014 | 6.839M |
| December 31, 2013 | 6.469M |
| September 30, 2013 | 6.874M |
| June 30, 2013 | 7.642M |
| March 31, 2013 | 6.167M |
| September 30, 2009 | 9.415M |
| June 30, 2009 | 11.09M |
| March 31, 2009 | 13.36M |
| December 31, 2008 | 15.18M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
-0.107M
Minimum
Sep 2019
36.59M
Maximum
Mar 2023
22.67M
Average
21.94M
Median
Research and Development Expense (TTM) Benchmarks
| AIM ImmunoTech Inc | 9.03M |
| Perspective Therapeutics Inc | 28.53M |
| Protalix BioTherapeutics Inc | 12.62M |
| Electromed Inc | 0.656M |
| Xtant Medical Holdings Inc | 2.145M |